CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
The recent communication regarding the recent Anti-SARS-CoV-2 Total assay in Tampa has brought about...
CTS will be revising some forms in use by clients on October 26, 2020. We do try to limit form chang...
CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...
Reminder test emails for the Health and Human Services (HHS) email notifications for WNV reactives h...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
The CTS forms listed below have been revised with an implementation date of September 2, 2019. ...